Pluripotent cells

{
  "publication_number": "US9439932B2",
  "country": "US",
  "kind": "B2",
  "title": "Pluripotent cells",
  "abstract": "Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.",
  "claims": [
    "1. A method of transplanting progenitor cells to a mammalian host, comprising: (a) obtaining a population of isolated mammalian progenitor cells that co-express nestin and Oct-4 from fetal telencephalon and/or mesencephalon, and a culture medium that has a total calcium concentration of 0.03 to 0.15 mM, wherein the progenitor cells are suspended in the culture medium and wherein the progenitor cells continue to proliferate in an undifferentiated state for at least 4 months; and (b) transplanting the progenitor cells to the mammalian host, wherein said progenitor cells further express a marker selected from the group consisting of TRA-1-60, TRA-1-81 and SSEA-4.",
    "2. The method of claim 1, wherein the isolated mammalian cells express each of TRA-1-60, TRA-1-81 and SSEA-4.",
    "3. The method of claim 1, wherein the cells have a doubling rate of less than 12 days.",
    "4. The method of claim 1, wherein the cells have a doubling rate of about 5 days.",
    "5. The method of claim 1, wherein the cells continue to proliferate for 2 years in vitro.",
    "6. The method of claim 1, wherein the subject is human, equine, canine, feline, porcine, ovine or rodent.",
    "7. The method of claim 1, wherein the medium has a total calcium concentration of less than 0.1 mM.",
    "8. The method of claim 7, wherein the total calcium concentration is about 0.05 mM.",
    "9. The method of claim 1, wherein the medium further comprises: (a) about 15-100 ng/μl epidermal growth factor (EGF); (b) about 10-150 ng/μl basic fibroblast growth factor (bFGF); (c) about 10-75 ng/μl transforming growth factor-alpha (TGFα).",
    "10. The method of claim 9, wherein the medium further comprises: (d) about 25-150 ng/μl leukemia inhibiting factor (LIF).",
    "11. The method of claim 10, wherein the LIF is about 25 ng/μl.",
    "12. The method of claim 9, wherein the EGF is about 20 ng/μl.",
    "13. The method of claim 9, wherein the bFGF is about 10 ng/μl.",
    "14. The method of claim 9, wherein the TGFα is about 10 ng/μl.",
    "15. The method of claim 9, wherein the culture medium is free of a feeder layer.",
    "16. The method of claim 9, wherein the culture medium is serum-free.",
    "17. The method of claim 9, further comprising 0.5-2.5% B27 supplement.",
    "18. The method of claim 9, wherein the growth factors EGF, bFGF and TGFα are recombinant growth factors.",
    "19. The method of claim 9, wherein the cells and the growth factors are human.",
    "20. The method of claim 9, wherein the culture medium further comprises about 0.11 mg/ml sodium pyruvate."
  ],
  "description_excerpt": "This application is a divisional of U.S. patent application Ser. No. 12/506,128, filed Jul. 20, 2009, now U.S. Pat. No. 8,367,406, which is a divisional of U.S. patent application Ser. No. 11/755,224, filed May 30, 2007, which claims the benefit of provisional patent application No. 60/803,619, filed May 31, 2006; and is a continuation-in-part of U.S. patent application Ser. No. 11/002,933, filed Dec. 2, 2004, now U.S. Pat. No. 7,632,681, which claims priority to provisional application No. 60/526,242, filed Dec. 2, 2003, the entire contents of each of which are incorporated by reference herein. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention pertains.\n\nParkinson's disease (PD) is a very common neurodegenerative disorder that affects more than 2% of the population over 65 years of age. PD is caused by a progressive degeneration and loss of dopamine (DA)-producing neurons, which leads to tremor, rigidity, and hypokinesia (abnormally decreased mobility). It is thought that PD may be the first disease to be amenable to treatment using stem cell transplantation. Factors that support this notion include the knowledge of the specific cell type (DA neurons) needed to relieve the symptoms of the disease. In addition, several laboratories have been successful in developing methods to induce embryonic stem cells to differentiate into cells with many of the functions of DA neurons.",
  "cpc": [
    "C12N 5/0623",
    "A01N 1/0205",
    "A01N 1/0221",
    "A01N 1/12",
    "A01N 1/125",
    "A61K 35/12",
    "A61K 35/30",
    "A61K 35/545",
    "A61P 25/08",
    "C12N 2500/14",
    "C12N 2500/38",
    "C12N 2500/46",
    "C12N 2500/90",
    "C12N 2501/11",
    "C12N 2501/115",
    "C12N 2501/148",
    "C12N 2501/235",
    "C12N 5/0607"
  ],
  "ipc": [
    "A61K 35/54",
    "A61K 35/30",
    "C12N 5/074",
    "C12N 5/0797",
    "A01N 1/02",
    "A61K 35/545",
    "C12N 5/00"
  ],
  "assignees": [
    "Celavie Biosciences LLC"
  ],
  "inventors": [
    "Oleg V. Kopyov"
  ],
  "filing_date": "2013-01-17",
  "publication_date": "2016-09-13",
  "grant_date": "2016-09-13",
  "priority_date": "2003-12-02",
  "application_number": "US-201313744262-A",
  "family_id": "46327972",
  "cited_by_count": 2,
  "citations": [
    "US6605275B1",
    "US5994617A",
    "US5811094A",
    "US5226914A",
    "US6294346B1",
    "US6071889A",
    "US5851832A",
    "US5750376A",
    "US5980885A",
    "US5981165A",
    "US6497872B1",
    "US6399369B1",
    "WO1994010292A1",
    "US5942435A",
    "US20030008392A1",
    "US6200806B1",
    "US5843780A",
    "US20010024825A1",
    "US6214369B1",
    "US5753506A",
    "US6040180A",
    "US6544787B1",
    "US5968829A",
    "US6498018B1",
    "EP1062321A1",
    "US6812027B2",
    "US20030100107A1",
    "US6821779B1",
    "US5958767A",
    "US6468794B1",
    "US6238922B1",
    "US6589759B1",
    "US7015037B1",
    "US6749850B1",
    "US6280718B1",
    "US6613568B2",
    "US20020178460A1",
    "US7468277B2",
    "US6395546B1",
    "US6610535B1",
    "US20040023376A1",
    "US6602711B1",
    "US20030190748A1",
    "US20010038836A1",
    "US6833269B2",
    "US20030166276A1",
    "US20090022696A1",
    "US20020155096A1",
    "US7517521B2",
    "US20050074880A1",
    "US7132286B2",
    "US20030013193A1",
    "US20030203844A1",
    "US20030068819A1",
    "US20030073234A1",
    "US7504100B2",
    "US20070116684A1",
    "US20030148512A1",
    "US7311905B2",
    "US20040005701A1",
    "US20050186193A1",
    "US20030228295A1",
    "US20080213276A1",
    "US7547522B2",
    "US20080003257A1",
    "US20040224401A1",
    "US20050042595A1",
    "US20090280097A1",
    "US20070269412A1",
    "US7632681B2",
    "US7534606B2",
    "US20090298045A1",
    "US20080031820A1",
    "US20070014773A1",
    "US20070026520A1",
    "US20080254513A1",
    "US20090022694A1",
    "US20070266448A1",
    "US20090253151A1",
    "US20100003754A1",
    "US20080233088A1",
    "US20080318316A1",
    "US20090324609A1",
    "US20090214484A1",
    "US20100209399A1"
  ]
}